Magnetic Resonance Imaging of the Lung: Oncological Applications
ConditionLung Cancer (NSCLC)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFondazione IRCCS Policlinico San Matteo di Pavia
About this trial
Lung neoplasms are characterized by a complex interaction between tumor cells and a variety of resident and infiltrating host elements, secreted factors, and extracellular matrix proteins, collectively referred to as the microenvironment. Nowadays, in the setting of lung cancer, and in particular non-small cell lung cancer (NSCLC), the evaluation of microenvironment characteristics can only be performed by a pathologist and only on histological material. By combining different MRI parameters, it may be possible to create a specific imaging "signature" for the three different immune phenotypes and thus be able to make a distinction based on MRI examination.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Primary NSCLC of the lung (TNM 8th edition T parameter ≥T1c)
Biopsy examination of the primary tumor adequate at least for PDL-1 quantification
Staging CT scan with uncertain N parameter and definite M parameter.
Disqualifiers
Absolute contraindications to magnetic resonance imaging or the administration of gadolinium-based contrast agents
Trial population
will be selected by the multidisciplinary thoracic neoplasms group (GINT) Patients with primary lung cancer
Trial design
Design model
Cohort
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
assessment of the ability of advanced magnetic resonance imaging techniques to distinguish between immune phenotypes in NSCLC.
Time frame
up to 36 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov